Literature DB >> 23527552

Proteomic biomarkers of endometrial cancer risk in women with polycystic ovary syndrome: a systematic review and biomarker database integration.

Nicolas Galazis1, Yik-Lam Pang, Myria Galazi, Zeina Haoula, Robert Layfield, William Atiomo.   

Abstract

There is a need for research studies into the molecular mechanisms underpinning the link between polycystic ovary syndrome (PCOS) and endometrial cancer (EC) to facilitate screening and to encourage the development of novel strategies to prevent disease progression. The objective of this review was to identify proteomic biomarkers of EC risk in women with PCOS. All eligible published studies on proteomic biomarkers for EC identified through the literature were evaluated. Proteomic biomarkers for EC were then integrated with an updated previously published database of all proteomic biomarkers identified so far in PCOS women. Nine protein biomarkers were similarly either under or over expressed in women with EC and PCOS in various tissues. These include transgelin, pyruvate kinase M1/M2, gelsolin-like capping protein (macrophage capping protein), glutathione S-transferase P, leucine aminopeptidase (cytosol aminopeptidase), peptidyl-prolyl cis-transisomerase, cyclophilin A, complement component C4A and manganese-superoxide dismutase. If validated, these biomarkers may provide a useful framework on which the knowledge base in this area could be developed and will facilitate future mathematical modelling to enhance screening and prevention of EC in women with PCOS who have been shown to be at increased risk.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23527552     DOI: 10.3109/09513590.2013.777416

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  5 in total

Review 1.  Multiomics Analysis-Based Biomarkers in Diagnosis of Polycystic Ovary Syndrome.

Authors:  Shikha Rani; Piyush Chandna
Journal:  Reprod Sci       Date:  2022-01-27       Impact factor: 3.060

2.  Expression of NAD(P)H quinone dehydrogenase 1 (NQO1) is increased in the endometrium of women with endometrial cancer and women with polycystic ovary syndrome.

Authors:  William Atiomo; Mohamad Nasir Shafiee; Caroline Chapman; Veronika M Metzler; Jad Abouzeid; Ayşe Latif; Amy Chadwick; Sarah Kitson; Vanitha N Sivalingam; Ian J Stratford; Catrin S Rutland; Jenny L Persson; Niels Ødum; Pablo Fuentes-Utrilla; Jennie N Jeyapalan; David M Heery; Emma J Crosbie; Nigel P Mongan
Journal:  Clin Endocrinol (Oxf)       Date:  2017-08-18       Impact factor: 3.478

3.  Lipidomics reveals altered biosynthetic pathways of glycerophospholipids and cell signaling as biomarkers of the polycystic ovary syndrome.

Authors:  Mariona Jové; Irene Pradas; Alba Naudí; Susana Rovira-Llopis; Celia Bañuls; Milagros Rocha; Manuel Portero-Otin; Antonio Hernández-Mijares; Victor M Victor; Reinald Pamplona
Journal:  Oncotarget       Date:  2017-12-17

Review 4.  Oncology and Pharmacogenomics Insights in Polycystic Ovary Syndrome: An Integrative Analysis.

Authors:  Verónica Yumiceba; Andrés López-Cortés; Andy Pérez-Villa; Iván Yumiseba; Santiago Guerrero; Jennyfer M García-Cárdenas; Isaac Armendáriz-Castillo; Patricia Guevara-Ramírez; Paola E Leone; Ana Karina Zambrano; César Paz-Y-Miño
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-26       Impact factor: 5.555

5.  Cisplatin Protein Binding Partners and Their Relevance for Platinum Drug Sensitivity.

Authors:  Sophie Möltgen; Eleonora Piumatti; Giuseppe M Massafra; Sabine Metzger; Ulrich Jaehde; Ganna V Kalayda
Journal:  Cells       Date:  2020-05-26       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.